This Article Full Text Full Text (PDF) All Versions of this Article: 114/25/2766    most recent CIRCULATIONAHA.106.642892v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saxon, L. A. Articles by Ecklund, F. Search for Related Content PubMed PubMed Citation Articles by Saxon, L. A. Articles by Ecklund, F. Related Collections Electrophysiology Other heart failure Ablation/ICD/surgery Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2006;114:2766-2772.)
© 2006 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Predictors of Sudden Cardiac Death and Appropriate Shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial

Leslie A. Saxon, MD; Michael R. Bristow, MD; John Boehmer, MD; Steven Krueger, MD; David A. Kass, MD; Teresa De Marco, MD; Peter Carson, MD; Lorenzo DiCarlo, MD; Arthur M. Feldman, MD, PhD; Elizabeth Galle, MS; Fred Ecklund, MS

From the Keck School of Medicine at the University of Southern California (L.A.S.), Los Angeles; University of Colorado Health Sciences Center (M.R.B.), Denver; Milton S. Hershey Medical Center (J.B.), Hershey, Pa; Bryan Memorial Hospital (S.K.), Lincoln, Neb; Johns Hopkins Hospital (D.A.K.), Baltimore, Md; University of California at San Francisco (T.D.M.), San Francisco; Veterans Affairs Medical Center (P.C.), Washington, DC; Pfizer Global Research and Development (L.D.), Ann Arbor, Mich; Jefferson Medical College (A.M.F.), Philadelphia, Pa; and Guidant Corporation (E.G., F.E.), St. Paul, Minn.

Correspondence to Leslie A. Saxon, MD, Cardiac Electrophysiology, USCUH, 1500 San Pablo Street, 2^nd Floor, Los Angeles, CA 90033. E-mail saxon{at}usc.edu

Received August 26, 2005; de novo received June 9, 2006; revision received October 5, 2006; accepted October 13, 2006.

Background— The factors that determine the risk for sudden death or implantable cardioverter defibrillator therapy in patients receiving cardiac resynchronization therapy (CRT) therapies are largely unknown.

Methods and Results— We hypothesized that clinical measures of heart failure severity and the presence of comorbid conditions would predict the risk of malignant arrhythmias in the 1520 patients enrolled in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial. Outcomes in the CRT group after implantable cardioverter defibrillator therapy were also evaluated. The CRT-defibrillator device reduced the risk of sudden death by 56% compared with drug therapy (17 of 595 [2.9%] versus 18 of 308 [5.8%], P<0.02). CRT therapy was not associated with sudden death risk reduction (48 of 617 [7.8%]). Other factors associated with reduced sudden death risk were left ventricular ejection fraction >20% (HR, 0.55 [95% CI, 0.35 to 0.87]; P=0.01), QRS duration >160 ms (HR, 0.63 [95% CI, 0.40 to 0.997]; P=0.05), and female gender (HR, 0.56 [95% CI, 0.34 to 0.94]; P=0.003). The risk for sudden death was increased by advanced New York Heart Association class IV heart failure (HR, 2.62 [95% CI, 1.61 to 4.26]; P<0.011) and renal dysfunction (HR, 1.69 [95% CI, 1.06 to 2.69]; P=0.03). An appropriate shock was experienced in 88 (15%) of the 595 CTR-D patients. In the CRT-defibrillator patients, female gender (HR, 0.54 [95 % CI, 0.31 to 0.94]; P=0.03) and use of neurohormonal antagonists were associated with reduced risk. Class IV heart failure status increased risk. Appropriate implantable cardioverter defibrillator therapy was positively associated with risk of death or all-cause hospitalization (HR, 1.57; P<0.002), pump failure death or hospitalization (HR, 2.35; P<0.001), and sudden death (HR, 2.99; P=0.03), but not total mortality (HR, 1.3; P=0.28).

Conclusions— In CRT candidates, sudden cardiac death risk is associated with higher New York Heart Association class and renal dysfunction. In CRT-defibrillator recipients, reduction in the risk of an appropriate shock is associated with medical therapy with neurohormonal antagonists, female gender, and New York Heart Association functional class III versus IV clinical status. Shock therapy was associated with worse outcome.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				F. Cabrera-Bueno, J. Fernandez-Pastor, M. J. Molina-Mora, J. Alzueta, J. L. Pena-Hernandez, A. Barrera, and E. de Teresa-Galvan Combined resynchronization therapy and automatic defibrillator in advanced non-ischaemic heart failure: the importance of QRS width Europace, January 1, 2010; 12(1): 92 - 95. [Abstract] [Full Text] [PDF]

				D. A. Pascual-Figal, J. Ordonez-Llanos, P. L. Tornel, R. Vazquez, T. Puig, M. Valdes, J. Cinca, A. B. de Luna, A. Bayes-Genis, and on behalf of the MUSIC Investigators Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. J. Am. Coll. Cardiol., December 1, 2009; 54(23): 2174 - 2179. [Abstract] [Full Text] [PDF]

				F. Cabrera-Bueno, M. J. Molina-Mora, J. Alzueta, J. Pena-Hernandez, M. Jimenez-Navarro, J. Fernandez-Pastor, A. Barrera, and E. de Teresa Persistence of secondary mitral regurgitation and response to cardiac resynchronization therapy Eur J Echocardiogr, November 24, 2009; (2009) jep184v1. [Abstract] [Full Text] [PDF]

				C. Leclercq, C. Daubert, and P. Mabo Not too late, not too fast!! Eur. Heart J., November 2, 2009; 30(22): 2689 - 2692. [Full Text] [PDF]

				J. C. Daubert, C. Leclercq, and P. Mabo Cardiac resynchronization therapy in combination with implantable cardioverter-defibrillator Europace, November 1, 2009; 11(suppl_5): v87 - v92. [Abstract] [Full Text] [PDF]

				J. P. Piccini, J. S. Berger, and C. M. O'Connor Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials Eur. Heart J., May 2, 2009; 30(10): 1245 - 1253. [Abstract] [Full Text] [PDF]

				M. A. Castel, F. Mendez, D. Tamborero, L. Mont, S. Magnani, J. M. Tolosana, A. Berruezo, M. Godoy, M. Sitges, B. Vidal, et al. Six-minute walking test predicts long-term cardiac death in patients who received cardiac resynchronization therapy Europace, March 1, 2009; 11(3): 338 - 342. [Abstract] [Full Text] [PDF]

				A. Lepillier, O. Piot, B. Gerritse, X. Copie, T. Lavergne, O. Paziaud, G. Lascault, X. Waintraub, A. Otmani, and J.-Y. Le Heuzey Relationship between New York Heart Association class change and ventricular tachyarrhythmia occurrence in patients treated with cardiac resynchronization plus defibrillator Europace, January 1, 2009; 11(1): 80 - 85. [Abstract] [Full Text] [PDF]

				J. G F Cleland, A. Tageldien, N. Maarouf, and N. Hobson Patients with heart failure who require an implantable defibrillator should have cardiac resynchronisation routinely Heart, August 1, 2008; 94(8): 963 - 966. [Full Text] [PDF]

				M. M. Sood, R. P. Pauly, C. Rigatto, and P. Komenda Left ventricular dysfunction in the haemodialysis population NDT Plus, August 1, 2008; 1(4): 199 - 205. [Abstract] [Full Text] [PDF]

				R. Deo, F. Lin, E. Vittinghoff, Z. H. Tseng, S. B. Hulley, and M. G. Shlipak Kidney Dysfunction and Sudden Cardiac Death Among Women With Coronary Heart Disease Hypertension, June 1, 2008; 51(6): 1578 - 1582. [Abstract] [Full Text] [PDF]

				R. A. Kloner and D. S. Cannom Uncertainty on the Use of Aldosterone Antagonists for Primary Therapy for Sudden Cardiac Death in the Setting of Implanted Devices Circulation, June 12, 2007; 115(23): 2983 - 2989. [Full Text] [PDF]